Trial · NCT06873763
Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer
NCT06873763, Phase 1, Phase 2, Recruiting, STCube, Inc.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer. Trials, record NCT06873763. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06873763
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer
- NCT number
- NCT06873763
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 52 participants, estimated
- Lead sponsor
- STCube, Inc.
- Conditions
- Metastatic Colorectal Cancer (CRC), Recurrent Colorectal Cancer
- Interventions
- Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab
- First posted
- 2025-03-13
- Last updated
- 2025-07-11
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of DLT | up to 6 months | Status of DLT will be presented with frequency, percentage and its 95% confidence interval (CI). |
| Primary | RP2D(Recommended Phase 2 Dose) | up to 2 years | The recommended phase 2 dose (RP2D) of nelmastobart in combination with trifluridine/tipiracil and bevacizumab |
| Primary | MTD(Maximum Tolerated Dose) | up to 2 years | To find the maximum tolerated dose (MTD) |
| Primary | Progression Free Survival (PFS) rate | up to 2 years | Time from the start of treatment to objective tumor progression or all-cause death will be presented with survival curve, median survival time and its 95% CI using the Kaplan-Meier estimation. |
| Secondary | Phase 2 study; Overall Survival (OS) | up to 2 years | Time from the start of treatment to all cause death |
| Secondary | Phase 2 study; Objective Response Rate (ORR) | up to 2 years | Investigator assessed ORR defined by RECIST 1.1 or iRECIST |
| Secondary | Maximum plasma concentration (Cmax) | up to 6 months | Maximum plasma concentration of Nelmastobart to evaluate PK parameters |
| Secondary | Phase 2 study; Disease Control Rate (DCR) | up to 2 years | Investigator assessed DCR at 16 weeks defined by RECIST 1.1 or iRECIST |
| Secondary | PFS(Progression free survival) | up to 2 years | Time from first dose until the date of objective disease progression or death |
| Secondary | Phase 2 study; Duration of Response (DOR) | up to 2 years | Time from the date of first confirmed objective response (CR or PR) after investigational drug administration to the first documented disease progression (PD) or death from any cause, with documentation of disease progression status and cause of death |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06873763
GET https://conductscience.org/api/trials/v1/NCT06873763/registered